Study of Nanocrystalline Megestrol Acetate with Chemoradiotherapy in Advanced Cervical Cancer

What this Trial Is About

Locally advanced cervical cancer is a common cancer in women worldwide and often leads to serious nutritional problems like malnutrition and cachexia. This condition worsens during concurrent chemoradiotherapy CCRT, especially due to treatments like platinum-based drugs, which cause muscle loss and weight loss, increasing mortality risk. Researchers are studying nanocrystalline megestrol acetate MA, a drug that may help stimulate appetite and reduce inflammation, aiming to improve nutritional status and treatment outcomes in these patients. This clinical trial compares two groups of patients with locally advanced cervical cancer undergoing CCRT one group will receive nanocrystalline megestrol acetate oral suspension at 625 mg daily for up to 8 weeks, and the other will receive CCRT alone. The nanocrystalline form of MA has better absorption and faster onset of effect than traditional forms, potentially leading to improved weight gain and reduced muscle wasting. The study will measure body mass index BMI, appetite, lean body mass, treatment completion, and side effects related to radiotherapy. Participants will be monitored for changes in BMI during the 8-week treatment period, alongside assessments of appetite using a specific scale, survival rates, and inflammatory markers. Regular lab tests will evaluate organ function and safety. The trial will also track adverse events and quality of life. The total participation duration for each patient is up to 8 weeks of treatment, with ongoing assessments to understand the drugs impact on nutrition and cancer treatment tolerance.

A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer